Can a smartphone app ease the burden of breast cancer hormone therapy?

NCT ID NCT06781996

Recruiting now Symptom relief Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a mobile app called Resilience© can improve quality of life for early-stage breast cancer patients undergoing hormone therapy. The app provides education, symptom management tips, and personalized support. 180 participants in France will be randomly assigned to use the app plus standard care, or standard care alone, for 12 weeks. The goal is to see if the app helps reduce side effects and improve well-being.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mobile app (Resilience© digital companion)
What this could lead to: If it works, this could give doctors a simple, scalable way to help breast cancer patients feel better during hormone therapy.
What could go wrong: This is a relatively small trial (180 people) testing a digital tool, not a drug. The effect on quality of life may be modest, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3)

Contacts and locations

Locations

Gustave Roussy
RECRUITING

Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.